Pharming Group’s (PHAR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research report sent to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $37.00 price objective on the stock. HC Wainwright also issued estimates for Pharming Group’s FY2026 earnings at $0.43 EPS and FY2027 earnings at $0.50 EPS.

Several other analysts have also issued reports on the stock. Canaccord Genuity Group boosted their price objective on shares of Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Zacks Research lowered shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $38.67.

Pharming Group Stock Up 0.5%

NASDAQ PHAR opened at $10.60 on Monday. The business’s fifty day simple moving average is $11.85 and its 200-day simple moving average is $13.71. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34. The firm has a market cap of $750.27 million, a PE ratio of 88.33 and a beta of 0.01. Pharming Group has a 52 week low of $9.62 and a 52 week high of $21.34.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. As a group, equities analysts anticipate that Pharming Group will post 0.22 earnings per share for the current year.

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.